Pancreatic Cancer Research

ResearcherShizuoka Cancer CenterActive in the last 2 years

Satoshi Kobayashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2535-6586; OpenAlex author ID A5034675205. Sources: OpenAlex.

Their work

Papers
57 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
132
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: 4 papers · 2017: 1 paper · 2018: 4 papers · 2019: 4 papers · 2020: 5 papers · 2021: 3 papers · 2022: 9 papers · 2023: 7 papers · 2024: 5 papers · 2025: 7 papers · 2026: 4 papers

Papers 50 of 57

  1. Plasma Protein Biomarkers for Early Detection of Pancreatic Cancer. Co-author DOI 10.1002/ijc.70637↗
  2. Associations Between Obesity, Diabetes Mellitus, and Pancreatic Cancer in the Japanese Population: A Mendelian Randomization Study. Co-author DOI 10.1111/cas.70344↗
  3. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  4. Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19380-z↗
  5. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  6. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  7. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. Co-author DOI 10.1016/j.pan.2025.02.005↗
  8. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  9. Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic… Co-author DOI 10.1177/17588359251351540↗
  10. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  11. Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18186-9↗
  12. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study. First author DOI 10.1007/s10147-023-02432-9↗
  13. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemc… Co-author DOI 10.1016/j.pan.2024.07.006↗
  14. Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. Co-author DOI 10.1111/pin.13416↗
  15. Clinical Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgical Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16805↗
  16. Clinical Impact of Preoperative Prognostic Nutritional Index in Surgical Patients With Pancreatic Cancer Treated With Perioperative Adjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.16970↗
  17. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  18. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  19. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  20. [Cutting edge of chemotherapy for advanced pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.120.629↗
  21. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational… Co-author DOI 10.1186/s12885-023-10654-3↗
  22. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection. Co-author DOI 10.1186/s12957-023-03141-3↗
  23. FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis. Co-author DOI 10.21873/anticanres.16601↗
  24. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysi… Co-author DOI 10.1002/cam4.4512↗
  25. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study. Co-author DOI 10.1016/j.pan.2022.06.004↗
  26. Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer. Co-author DOI 10.1080/01635581.2020.1871495↗
  27. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  28. Management of elderly patients with unresectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyac101↗
  29. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  30. Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel. Co-author DOI 10.1097/mpa.0000000000001985↗
  31. Authors' reply to the Letter to the Editor: Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. First author DOI 10.1111/cas.15324↗
  32. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus … Co-author DOI 10.3892/ol.2022.13495↗
  33. A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s10147-021-02001-y↗
  34. Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials. Co-author DOI 10.1097/mpa.0000000000001879↗
  35. Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Co-author DOI 10.1111/cas.15106↗
  36. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Co-author DOI 10.1016/j.pan.2020.07.006↗
  37. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  38. A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001484↗
  39. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-insti… Co-author DOI 10.21873/invivo.11780↗
  40. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuva… Co-author DOI 10.4103/jcrt.jcrt_440_18↗
  41. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japa… Co-author DOI 10.1016/j.pan.2019.01.001↗
  42. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Co-author DOI 10.1111/cas.13883↗
  43. Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.26633↗
  44. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. Co-author DOI 10.7150/jca.28660↗
  45. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Co-author DOI 10.1097/mpa.0000000000001049↗
  46. Prediction model for pancreatic cancer risk in the general Japanese population. Co-author DOI 10.1371/journal.pone.0203386↗
  47. The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.12801↗
  48. Survival and the prognosticators of peritoneal cytology-positive pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy. Co-author DOI 10.4103/0973-1482.194927↗
  49. Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemoth… Co-author DOI 10.3892/ol.2017.6295↗
  50. Duodenal stenting followed by systemic chemotherapy for patients with pancreatic cancer and gastric outlet obstruction. Co-author DOI 10.1016/j.pan.2016.07.007↗

Closest collaborators

The 25 strongest of 132 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 48 shared papers, 2014–2026 · strength 6.34
  2. Junji Furuse · 16 shared papers, 2021–2026 · strength 2.77
  3. Manabu Morimoto · 25 shared papers, 2014–2024 · strength 2.37
  4. Masato Ozaka · 17 shared papers, 2018–2026 · strength 2.20
  5. Soichiro Morinaga · 19 shared papers, 2014–2026 · strength 1.86
  6. Masaaki Murakawa · 17 shared papers, 2014–2026 · strength 1.84
  7. Masafumi Ikeda · 12 shared papers, 2020–2026 · strength 1.73
  8. Naoto Yamamoto · 13 shared papers, 2014–2025 · strength 1.57
  9. Naohiro Okano · 11 shared papers, 2018–2025 · strength 1.34
  10. Toru Aoyama · 16 shared papers, 2014–2025 · strength 1.33
  11. Shun Tezuka · 10 shared papers, 2016–2025 · strength 1.28
  12. Akiko Todaka · 11 shared papers, 2018–2025 · strength 1.27
  13. Hiroshi Ishii · 9 shared papers, 2018–2026 · strength 1.27
  14. Shin Maeda · 7 shared papers, 2022–2026 · strength 1.22
  15. Yohei Miyagi · 8 shared papers, 2016–2026 · strength 1.16
  16. Yuto Kamioka · 6 shared papers, 2020–2026 · strength 1.03
  17. Nobumasa Mizuno · 10 shared papers, 2018–2023 · strength 1.00
  18. Hiroshi Imaoka · 7 shared papers, 2020–2025 · strength 0.99
  19. Shinnosuke Kawahara · 5 shared papers, 2023–2026 · strength 0.93
  20. Shuhei Nagashima · 6 shared papers, 2021–2024 · strength 0.93
  21. Takuji Okusaka · 7 shared papers, 2016–2026 · strength 0.90
  22. Chigusa Morizane · 6 shared papers, 2021–2025 · strength 0.89
  23. Naoki Sasahira · 6 shared papers, 2018–2026 · strength 0.89
  24. Yuichiro Tozuka · 5 shared papers, 2020–2025 · strength 0.82
  25. Takeshi Terashima · 5 shared papers, 2023–2025 · strength 0.80

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.